Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 2/20 | 0.43 |
| ▸ | FEN1 | P39748 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 3/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15009785 | 1.00 | ALOX5AP (0.43) | ALOX5APFEN1EPHX2MEN1ALDH1A1 | |
| SCHEMBL30553370 | 0.89 | EPHX2 (0.39) | ALOX5APFEN1EPHX2MEN1ALDH1A1 | |
| SCHEMBL14684308 | 0.87 | ADRA1A (0.43) | ALOX5APFEN1EPHX2MEN1ALDH1A1 | |
| SCHEMBL27872324 | 0.85 | EPHX2 (0.43) | ALOX5APFEN1EPHX2MEN1ALDH1A1 | |
| SCHEMBL30214832 | 0.83 | KIF11 (0.47) | ALOX5APFEN1EPHX2MEN1ALDH1A1 | |
| SCHEMBL2182720 | 0.83 | KIF11 (0.47) | ALOX5APFEN1EPHX2MEN1ALDH1A1 | |
| SCHEMBL28230701 | 0.82 | ALOX5AP (0.46) | ALOX5APFEN1MEN1ALDH1A1TSHR | |
| SCHEMBL17927016 | 0.82 | DDR1 (0.43) | EPHX2 | |
| SCHEMBL30214735 | 0.81 | ALDH1A1 (0.43) | ALOX5APFEN1EPHX2MEN1ALDH1A1 | |
| SCHEMBL310121 | 0.81 | ALDH1A1 (0.43) | ALOX5APFEN1EPHX2MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| CN-119301113-A | Novel heterocyclic carbonyl cyclic compounds as MAGL inhibitors | 豪夫迈·罗氏有限公司 | 2025-01-10 | — | — | CN | disclosed |
| US-20240383904-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-11-21 | — | — | US | disclosed |
| US-20240262806-A1 | INHIBITORS OF NLRP3 | PCT THERAPEUTICS, INC. (US) | 2024-08-08 | — | — | US | disclosed |
| CN-118302417-A | NLRP3 inhibitors | PTC医疗公司 | 2024-07-05 | — | — | CN | disclosed |
| WO-2023247670-A1 | NEW HETEROCYCLIC-CARBONYL-CYCLIC COMPOUNDS AS MAGL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240262806-A1 | INHIBITORS OF NLRP3 | NLRP3, NOD1, NLRP1 | ALOX5AP 1247/4885FEN1 4354/4885EPHX2 2370/4885 |
| US-20240383904-A1 | HETEROCYCLIC COMPOUNDS | MAGI3, MAG, MAGT1 | ALOX5AP 2101/4885FEN1 3485/4885EPHX2 256/4885 |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | ALOX5AP 2464/4885FEN1 4564/4885EPHX2 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.